Drugs / VIOKASE16
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00559052 | Mar 2008 → Feb 2009 | exocrine pancreatic insufficiency | Axcan Pharma | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00559364 | Nov 2007 → Jul 2009 | chronic pancreatitis, exocrine pancreatic insufficiency | Forest Laboratories | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Viokase 16 | “The Viokase 16 is to be taken as 3 tablets with the liquid meal during perfusion procedure.” NCT00559052 ↗ |
| Modality | Protein / enzyme biologic | “porcine pancreatic enzyme concentrate, consisting mainly of lipase, amylase and protease” NCT00559052 ↗ |
| Route | Oral | “Patients assigned to Viokase® 16 will be given 22 tablets orally daily” NCT00559364 ↗ |